Pharmacological and clinical evaluation of romiplostim
ZHU Yi
FU De-xing
Abstract：Idiopathic thrombocytopenic purpura (ITP) is an autoimmune disease, in which platelets were destructed due to the effects of antiplatelet antibodies, causing severe bleeding. Cortieosteroids, immunosuppressants, anti-CD20 antibody and splenectomy have been used for the conventional therapy of ITP. However, relapse and adverse reactions occurred frequently after the conventional therapy. Romiplostim is a recombinant Fc-peptide fusion protein which could increase platelet counts in patients with chronic ITP. Its action mechanism, pharmacodynamies, pharmacokinetics and clinical therapeutics of romiplostim were reviewed in this paper.
Keywords：romiplostimidiopathic thrombocytopenic purpurapharmacologyclinical evaluation
Publication Date：2010-01-01
Online Publishing Date：2026-08-14(First online date of this platform, not the publication date of the document)
Pages：3( 461-463 )